Treatment of stage 3 chronic kidney disease

Treatment of stage 3 chronic kidney disease

Treatment of stage 3 chronic kidney disease(CKD) is increasing, and Treatment of stage 3 chronic kidney disease patients are at risk for severe adverse outcomes such as progressive loss of kidney function, cardiovascular (CV) disease, and premature death [1]. CKD-Mineral and Bone Disorder (CKD-MBD) is the clinical syndrome that develops as a systemic disorder of bone and mineral metabolism due to CKD, which is manifested by abnormalities in bone and mineral metabolism [1]. Alterations in calcium and phosphate metabolism that are frequently observed in secondary hyperparathyroidism of uremia (SHPT), particularly in patients with maintenance hemodialysis, contribute to ectopic calcification, CV disease, and the risk of death [2].

Hypertension is a major risk factor for cardiovascular and renal disease. Conversely, Treatment of stage 3 chronic kidney disease (CKD) is the most common form of secondary hypertension and mounting evidence suggests it is an independent risk factor for cardiovascular morbidity and mortality [1–3]. The prevalence of CKD has been better characterized since the National Kidney Foundation issued a standard classification based on the level of glomerular filtration rate (GFR) and the presence or absence of evidence of renal injury. Patients with stages 1 and 2 CKD need to show evidence of renal injury (e.g., proteinuria), and GFR of ≥90 and 60–89 mL/minute, respectively. Stages 3, 4, and 5 correspond to GFR of 30–59, 15–29, and <15 mL/minute, respectively, regardless of any other evidence of renal damage [4]. It is estimated that 10–13% of adults in the USA suffer from some degree of CKD [5].

Evidence from a large number of clinical trials has clearly demonstrated that effective treatment ameliorates the harmful effects of uncontrolled hypertension [6]. Unfortunately, most trials have excluded patients with CKD, and those trials that specifically targeted CKD patients primarily focused on progression of renal disease as the primary clinical endpoint. In this paper, we review the epidemiology, pathophysiology, and therapy of hypertension in CKD and highlight the gaps in the available evidence.

The optimum dosing regimen for rituximab is unknown. There are two widely used schedules. The first developed for use in lymphoma consists of four weekly intravenous doses of 375 mg/m2, while in treating autoimmune disease, two 1 g intravenous doses given 2 weeks apart are used. However, neither is used exclusively (the 2 × 1 g regimen was used in the main systemic lupus erythematosus (SLE) trials while the 375 mg/m2 regimen was used in AAV trials) and variations of these regimens, including those based on the degree of B-cell depletion, are used in some cohort studies, as outlined below. Further work is really needed to establish what the most cost-efficient and efficacious method of drug delivery is.

http://www.sjzkidneyhospital.com/tags.php?/CKD+Treatment/